University of Bologna, Internal medicine, Aging and Kidney Diseases Department, Bologna, Italy.
Expert Opin Pharmacother. 2012 Oct;13(14):1999-2003. doi: 10.1517/14656566.2012.708733. Epub 2012 Jul 18.
The increasing worldwide prevalence of hypertension and the related increase in cost due to diagnosis, management and negative outcomes forces public health institutions and clinical researchers to find new strategies to improve blood pressure (BP) control. So what are the possible future perspectives for high BP management?
Three main points are briefly discussed in this article: individualized therapy, the known genetic contribution to hypertension development and control, and the improvement of disease management, including perspectives on new antihypertensive drug development.
It is likely that the integration of the best available current knowledge with recent diagnostic and therapeutic achievements for the management of hypertension prevention and treatment will lead to the early detection of at-risk conditions, early diagnosis, and individualized and efficacious treatment. The most promising antihypertensive drugs currently in development are innovative renin-angiotensin-aldosterone system modulators. Further drugs have potentially interesting mechanisms of action, but renalase analogs are in the very early phases of development, and available endothelin antagonists have a poor safety profile.
高血压在全球范围内的患病率不断上升，诊断、管理和不良后果所导致的费用增加，迫使公共卫生机构和临床研究人员寻找新的策略来改善血压（BP）控制。那么，高血压管理的未来可能会有哪些新的视角呢？
本文简要讨论了三个主要观点：个体化治疗、已知的高血压发展和控制的遗传贡献，以及疾病管理的改善，包括新降压药物开发的前景。
将目前可获得的最佳知识与高血压预防和治疗管理的最新诊断和治疗成果相结合，很可能会导致早期发现高危情况、早期诊断以及个体化和有效的治疗。目前最有前途的降压药物是创新性的肾素-血管紧张素-醛固酮系统调节剂。还有一些药物具有潜在的有趣作用机制，但肾酶类似物处于非常早期的开发阶段，而现有的内皮素拮抗剂安全性较差。
